Live Breaking News & Updates on Cymabay therapeutics inc

Stay informed with the latest breaking news from Cymabay therapeutics inc on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Cymabay therapeutics inc and stay connected to the pulse of your community

CymaBay Therapeutics (NASDAQ:CBAY) Receives New Coverage from Analysts at StockNews.com

CymaBay Therapeutics (NASDAQ:CBAY) Receives New Coverage from Analysts at StockNews.com
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

China , Piper-sandler , Janet-dorling , Raymond-james , Wetzel-investment-advisors-inc , Cymabay-therapeutics-inc , Tucker-asset-management , Harvest-fund-management-co , China-universal-asset-management-co , Nasdaq , Cymabay-therapeutics , Free-report

CymaBay Therapeutics (NASDAQ:CBAY) Coverage Initiated at StockNews.com

CymaBay Therapeutics (NASDAQ:CBAY) Coverage Initiated at StockNews.com
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

New-york , United-states , William-blair , Janet-dorling , Raymond-james , Cantor-fitzgerald , Emerald-mutual-fund-advisers , Nasdaq , Cymabay-therapeutics-company-profile , Emerald-advisers , Vanguard-group-inc , Cymabay-therapeutics-inc

Gilead Sciences Announces First Quarter 2024 Financial Results

25.04.2024 - Gilead Sciences, Inc. (Nasdaq: GILD) announced today its first quarter 2024 results of operations. “Gilead delivered another strong quarter of revenue growth in the first quarter with 6% year-over-year growth in our base business driven by HIV, ...

Foster-city , California , United-states , Ireland , America , Complera-eviplera , Kevin-lofton , Sofosbuvir-velpatasvir , Anthony-welters , European-union , Immunomedics-inc , Xilio-therapeutics-inc

3 Potential Biopharma Buyout Targets

3 Potential Biopharma Buyout Targets
seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.

United-states , Canada , Stifel-nicolaus , Novo-nordisk , Eli-lilly , Gilead-sciences-inc , Company-website , Mirum-pharmaceuticals-inc , Pipeline-company-website , Immunogen-inc , Cymabay-therapeutics-inc , Company-presentation

Jennison Associates LLC Increases Holdings in CymaBay Therapeutics, Inc. (NASDAQ:CBAY)

Jennison Associates LLC lifted its holdings in shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Free Report) by 12.3% during the 4th quarter, Holdings Channel.com reports. The firm owned 3,992,711 shares of the biopharmaceutical company’s stock after buying an additional 437,437 shares during the quarter. Jennison Associates LLC’s holdings in CymaBay Therapeutics were worth $94,308,000 at […]

Piper-sandler , Raymond-james , Janet-dorling , Nasdaq , Jennison-associates , Clarius-group , Securities-exchange-commission , International-assets-investment-management , Calamos-advisors , Cymabay-therapeutics-inc , Holdings-channel , Allspring-global-investments-holdings

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Receives Average Recommendation of "Hold" from Analysts

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Receives Average Recommendation of "Hold" from Analysts
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

William-blair , Janet-dorling , Raymond-james , Charles-mcwherter , Vanguard-group-inc , Pricet-rowe-associates-inc , Blackrock-inc , Avoro-capital-advisors , Nasdaq , Cymabay-therapeutics-inc , Cymabay-therapeutics , Get-free-report

Cancer-Drug Maker Janux Therapeutics Weighs Possible Sale

Cancer-Drug Maker Janux Therapeutics Weighs Possible Sale
bnnbloomberg.ca - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bnnbloomberg.ca Daily Mail and Mail on Sunday newspapers.

Denmark , New-york , United-states , Danish , Gilead-sciences-inc , Bloomberg , Bloomberg-drugmaker-janux-therapeutics-inc , Profoundbio-inc , Cymabay-therapeutics-inc , Janux-therapeutics , Diego-based-janux

CymaBay Therapeutics (NASDAQ:CBAY) Earns Sell Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of CymaBay Therapeutics (NASDAQ:CBAY – Free Report) in a report released on Wednesday. The brokerage issued a sell rating on the biopharmaceutical company’s stock. Several other research analysts have also commented on CBAY. Piper Sandler reaffirmed a neutral rating and issued a $32.50 price target (down from $33.00) on shares […]

New-york , United-states , Piper-sandler , Janet-dorling , Raymond-james , Pault-quinlan , Jennison-associates , Cantor-fitzgerald , Cymabay-therapeutics-inc , York-state-common-retirement-fund , Emerald-mutual-fund-advisers , Emerald-advisers

CymaBay Therapeutics (NASDAQ:CBAY) Now Covered by Analysts at StockNews.com

CymaBay Therapeutics (NASDAQ:CBAY) Now Covered by Analysts at StockNews.com
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

William-blair , Charles-mcwherter , Janet-dorling , Piper-sandler , Strategic-blueprint , Harvest-fund-management-co , Chartwell-investment-partners , Securities-exchange-commission , Cymabay-therapeutics-inc , Alps-advisors-inc , Mirae-asset-global-investments-co , Cymabay-therapeutics

Assenagon Asset Management S.A. Invests $17.63 Million in CymaBay Therapeutics, Inc. (NASDAQ:CBAY)

Assenagon Asset Management S.A. purchased a new position in shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 746,353 shares of the biopharmaceutical company’s stock, valued at approximately $17,629,000. Assenagon Asset Management […]

New-york , United-states , Daniel-menold , Piper-sandler , Janet-dorling , Emerald-advisers , Jennison-associates , Emerald-mutual-fund-advisers , Cymabay-therapeutics-inc , York-state-common-retirement-fund , Nasdaq , Exchange-commission